Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease

Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease

Background: Anti-integrin therapy is a new frontline strategy in the treatment of inflammatory bowel diseases (IBD). The anti-β7 integrin antibody etrolizumab is currently being investigated for safety and efficacy in Crohn’s disease (CD) and ulcerative colitis (UC) in several phase III trials. Mech...

Full description

Bibliographic Details
Main Authors: Charlotte Lichnog, Sha Klabunde, Emily Becker, Franklin Fuh, Philipp Tripal, Raja Atreya, Entcho Klenske, Rich Erickson, Henry Chiu, Chae Reed, Shan Chung, Clemens Neufert, Imke Atreya, Jacqueline McBride, Markus F. Neurath, Sebastian Zundler
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-02-01
Series:Frontiers in Pharmacology
Subjects:
etrolizumab
inflammatory bowel diseases
internalization
STED microscopy
adhesion
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.00039/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2019.00039/full

Similar Items